TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25227570

Group type: EXPERIMENTAL
Intervention: Keyboard/mouse tray (KBT), touch pad (TP) for the non-dominant hand, and keyboard shortcuts
Number of subjects: 113

Group type: COMPARATOR
Intervention: Keyboard shortcuts
Number of subjects: 113
Study: 23075127

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES) with a molecular weight of 130 kD and a molar substitution ratio of 0.4 (130/0.4, Voluven) in 0.9% sodium chloride
Number of subjects: 7000

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES)
Number of subjects: 7000
Study: 20973220

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (N)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Direct operation group (D)
Number of subjects: 63
Study: 18606041

Group type: EXPERIMENTAL
Intervention: Therapeutic intervention for foster preschoolers
Number of subjects: 177

Group type: COMPARATOR
Intervention: Regular foster care condition
Number of subjects: 177
Study: 16039331

Group type: EXPERIMENTAL
Intervention: Radiotherapy (para-aortic strip or dog-leg field; n=904)
Number of subjects: 1477

Group type: EXPERIMENTAL
Intervention: Carboplatin (one injection, dose based on the formula 7x[glomerular filtration rate+25] mg; n=573)
Number of subjects: 1477

Group type: COMPARATOR
Intervention: Carboplatin (n=573)
Number of subjects: 1477

Group type: COMPARATOR
Intervention: Radiotherapy (n=904)
Number of subjects: 1477
Study: 11942473

Group type: EXPERIMENTAL
Intervention: Fish meals (fatty fish)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fish oil (2-8 g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fish meals and fish oil supplements
Number of subjects: 24
Study: 10491416

Group type: EXPERIMENTAL
Intervention: Alcohol (Everclear-R)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alcohol-induced liver disease (ALD)
Number of subjects: 10
Study: 8673651

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Mental health
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Subjective religiosity
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Being African American
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Perceived health
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Being Catholic
Number of subjects: 1051
Study: 1761810

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.6 U/kg/week sc 5‐6 times/week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-dose oxandrolone 0.07 mg/kg po
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both GH and oxandrolone
Number of subjects: 16

Group type: COMPARATOR
Intervention: GH or oxandrolone
Number of subjects: 16
Study: 6366806

Group type: EXPERIMENTAL
Intervention: 4 mg salbutamol 3-times daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 20 micrograms clenbuterol twice daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 40 micrograms clenbuterol twice daily
Number of subjects: 48
Study: 31810217

Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle intervention
Number of subjects: 629

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 629
Study: 30358674

Group type: EXPERIMENTAL
Intervention: Single-Family Room (SFR)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Open Bay (OB)
Number of subjects: 115
Study: 27364038

Group type: EXPERIMENTAL
Intervention: Amalaki rasayana
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25098981

Group type: EXPERIMENTAL
Intervention: Levamisole (vermisole 150 mg, once daily for the first 3 days of 3 weeks in a month for 3 months with a gap of 1 week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no levamisole)
Number of subjects: 30
Study: 22212648

Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha plus ribavirin therapy
Number of subjects: 526
Study: 20587064

Group type: EXPERIMENTAL
Intervention: De Palma percutaneous pinning
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bridging external fixation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 17414740

Group type: EXPERIMENTAL
Intervention: Amisulpride (200-800 mg/day)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 377
Study: 17215640

Group type: EXPERIMENTAL
Intervention: Resistance training group
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Aerobic walking group
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Combined exercise group
Number of subjects: 131

Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 131
Study: 15498373

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion (acu‐moxi) alone
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion (acu‐moxi) in combination with prednisone, Vitamin B1, vitamin B12, and dibazole
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (prednisone, vitamin B1, vitamin B12, and dibazole)
Number of subjects: 480
Study: 10694777

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Green tea (2 g tea solids in 300 ml water)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Black tea with milk
Number of subjects: 21

Group type: COMPARATOR
Intervention: Green tea with milk
Number of subjects: 21

Group type: COMPARATOR
Intervention: Water
Number of subjects: 21
Study: 9351400

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (RRR-AT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: all-racemic alpha-tocopherol (all-rac-AT)
Number of subjects: 79
Study: 1389935

Group type: EXPERIMENTAL
Intervention: Sublingual verapamil 40 mg (Securon)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral verapamil 40 mg (Securon)
Number of subjects: 6
Study: 3934544

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 6
Study: 31050143

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Dulaglutide 3.0 mg
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Dulaglutide 4.5 mg
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 29211866

Group type: EXPERIMENTAL
Intervention: 1.0 mmol/kg/d potassium bicarbonate (KHCO3)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 1.5 mmol/kg/d potassium bicarbonate (KHCO3)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 26359449

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 23057502

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22212494

Group type: EXPERIMENTAL
Intervention: 2% diltiazem ointment
Number of subjects: 93

Group type: COMPARATOR
Intervention: 0.2% glyceryl trinitrate
Number of subjects: 93

Group type: COMPARATOR
Intervention: 10% lidocaine
Number of subjects: 93
Study: 20299984

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (no N-acetylcysteine)
Number of subjects: 74
Study: 17583595

Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg kg‐1 (Group I, n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Magnesium 30 mg kg‐1 (Group II, n = 40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (Group III, n = 40)
Number of subjects: 120
Study: 15604003

Group type: EXPERIMENTAL
Intervention: Stationary wheelchair ergometer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Motor-driven treadmill
Number of subjects: 30

Group type: COMPARATOR
Intervention: Circular wheelchair track
Number of subjects: 30
Study: 12197844

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg twice daily for 8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (identical capsules for 8 weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 28
Study: 9451563

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling from the center and 12:00 region
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling from 3 sequential regions
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling from 4 sequential regions
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling from the center region
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling including the 12:00 region
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Resection of nodules characterized as malignant (M) or suspicious/neoplastic (S/N)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Follow-up of benign (B) nodules
Number of subjects: 74
Study: 7892843

Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (monitored group)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Routine high-risk prenatal care alone (unmonitored group)
Number of subjects: 218
Study: 2496434

Group type: EXPERIMENTAL
Intervention: Nicotine smoke-free cigarettes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo smoke-free cigarettes
Number of subjects: 40
Study: 1015009

Group type: EXPERIMENTAL
Intervention: Cendehill vaccination
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: RA 27/3 vaccination
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (not protected by natural immunity or vaccination)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (protected by natural immunity)
Number of subjects: 159
Study: 30773863

Group type: EXPERIMENTAL
Intervention: IHTAN + acupoint injection
Number of subjects: 88

Group type: COMPARATOR
Intervention: Warm needle moxibustion + acupoint injection
Number of subjects: 88

Group type: COMPARATOR
Intervention: Acupoint injection
Number of subjects: 88
Study: 30238433

Group type: EXPERIMENTAL
Intervention: Riociguat 2 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27262302

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 200
Study: 24189477

Group type: EXPERIMENTAL
Intervention: CRT with defibrillator (CRT-D)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: CRT without defibrillator back-up
Number of subjects: 259
Study: 22805294

Group type: EXPERIMENTAL
Intervention: 10% w/v calcium phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) paste
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 296
Study: 20808092

Group type: EXPERIMENTAL
Intervention: Home-delivered problem adaptation therapy (PATH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Home-delivered supportive therapy (ST)
Number of subjects: 30
Study: 17209889

Group type: EXPERIMENTAL
Intervention: Spaced education consisting of weekly e-mailed case scenarios and clinical questions on 2 of the 4 urology topics.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (not specified in detail, but implied to be students who did not receive spaced education).
Number of subjects: 95
Study: 16420078

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 230

Group type: COMPARATOR
Intervention: Reboxetine
Number of subjects: 230
Study: 12934761

Group type: EXPERIMENTAL
Intervention: E-Mousse (20% acetate vitamin E) applied twice daily for 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (contralateral leg untreated)
Number of subjects: 40
Study: 10367574

Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring segment (ICRS) procedure
Number of subjects: 94
Study: 8916997

Group type: EXPERIMENTAL
Intervention: Blind vaginal swab technique
Number of subjects: 88

Group type: COMPARATOR
Intervention: Speculum examination
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 88
Study: 1913767

Group type: EXPERIMENTAL
Intervention: Least thorough rinsing procedure (5 ml x 2 s once)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Most thorough rinsing procedure (20 ml x 10 s twice)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Increasing rinse volume, rinse duration, and rinse frequency
Number of subjects: 8
Study: 6130066

Group type: EXPERIMENTAL
Intervention: buspirone (average 16.5 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: diazepam (15 mg/day)
Number of subjects: 100
Study: 30880505

Group type: EXPERIMENTAL
Intervention: 550 mg of MYO + 150 mg of DCI twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: 550 mg of MYO + 13.8 mg of DCI twice daily
Number of subjects: 60
Study: 30043130

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nilotinib
Number of subjects: 81
Study: 26850310

Group type: EXPERIMENTAL
Intervention: Weekly nutrition lessons focused on benefits of fruit and vegetable consumption
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Weekly nutrition lessons and provision of one serving of fruits and two servings of vegetables per day for 10 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 54
Study: 24642201

Group type: EXPERIMENTAL
Intervention: Almond consumption (0, 1.5, or 3 servings/day for 18 days)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pistachio consumption (0, 1.5, or 3 servings/day for 18 days)
Number of subjects: 34
Study: 21819279

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment for 10 weeks
Number of subjects: 34
Study: 20652463

Group type: EXPERIMENTAL
Intervention: Web-based personalized genetic feedback
Number of subjects: 200

Group type: COMPARATOR
Intervention: Attention-control feedback
Number of subjects: 200
Study: 17435110

Group type: EXPERIMENTAL
Intervention: standard forecast + UV
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: standard forecast + UV + sun-protection messages
Number of subjects: 557

Group type: COMPARATOR
Intervention: standard forecast (no UV)
Number of subjects: 557
Study: 15755866

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (850 mg/d)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 12409108

Group type: EXPERIMENTAL
Intervention: MDT specialist CT (n=60)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control CT (n=50)
Number of subjects: 110
Study: 9040677

Group type: EXPERIMENTAL
Intervention: ACAS surgical patients
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: ACAS-eligible patients not enrolled and ACAS surgeons
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: ACAS-eligible patients not enrolled and non-ACAS surgeons
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: ACAS-ineligible patients and ACAS surgeons
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: ACAS-ineligible patients and non-ACAS surgeons
Number of subjects: 277
Study: 7893868

Group type: EXPERIMENTAL
Intervention: Ceftazidime (120 mg/[kg.d])
Number of subjects: 379

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (160 mg/[kg.d])
Number of subjects: 379
Study: 2447403

Group type: EXPERIMENTAL
Intervention: epanolol, 200 mg b.i.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: pindolol, 10 mg b.i.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: epanolol, 400 mg q.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: pindolol, 10 mg b.i.d. and epanolol, 200 mg b.i.d.
Number of subjects: 30
Study: 31219519

Group type: EXPERIMENTAL
Intervention: Optimal controls in randomized clinical trials
Number of subjects: 79

Group type: COMPARATOR
Intervention: Suboptimal controls for genitourinary tumors
Number of subjects: 79

Group type: COMPARATOR
Intervention: Suboptimal controls for lung/head and neck tumors
Number of subjects: 79
Study: 29608967

Group type: EXPERIMENTAL
Intervention: Chemotherapy in older patients (65 years and older)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Chemotherapy in younger patients (younger than 65 years)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Older patients (65 years and older)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 1006
Study: 26520004

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24121497

Group type: EXPERIMENTAL
Intervention: Standard NHS cardiac rehabilitation programme
Number of subjects: 24
Study: 22561596

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 0.2 mg orally
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19508877

Group type: EXPERIMENTAL
Intervention: Intrinsic visual cues (scene structure, horizon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extrinsic visual cues (support structures)
Number of subjects: 0
Study: 17991531

Group type: EXPERIMENTAL
Intervention: 3-day standard bowel preparation (group 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Soft diet with no oral intake 8 hours before surgery (group 2)
Number of subjects: 62
Study: 15356967

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 114

Group type: COMPARATOR
Intervention: Calcium Carbonate (CC)
Number of subjects: 114
Study: 12006190

Group type: EXPERIMENTAL
Intervention: 532 nm, 2 ms pulse-duration Nd:YAG laser treatment for upper lip wrinkles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 532 nm, 2 ms pulse-duration Nd:YAG laser treatment for facial acne scarring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated side) for upper lip wrinkles and facial acne scarring
Number of subjects: 0
Study: 9893933

Group type: EXPERIMENTAL
Intervention: Test 1 (chewable tablets containing 76 mg Na2FPO3 and 1250 mg calcium carbonate)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Test 2 (effervescent tablets containing 76 mg Na2FPO3 and 1250 mg calcium carbonate)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ref1 (tablets containing 76 mg Na2FPO3)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ref2 (effervescent tablets containing 76 mg Na2FPO3 and 3240 mg calcium lactogluconate/carbonate)
Number of subjects: 38
Study: 8064320

Group type: EXPERIMENTAL
Intervention: Physostigmine (anti-cholinesterase)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Scopolamine (anticholinergic)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated Alzheimer patients
Number of subjects: 12
Study: 2840815

Group type: EXPERIMENTAL
Intervention: Lisinopril 2.5 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lisinopril 5.0 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lisinopril (various doses)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 55
Study: 8018302

Group type: EXPERIMENTAL
Intervention: Drug treatments to reduce hypertension and hyperlipidaemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer models for estimating long term benefits of risk factor modification
Number of subjects: 0
Study: 368370

Group type: EXPERIMENTAL
Intervention: Vitamin C prophylaxis, 2.0 g/day
Number of subjects: 674

Group type: COMPARATOR
Intervention: Placebo prophylaxis
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Vitamin C prophylaxis
Number of subjects: 674
Study: 31794152

Group type: EXPERIMENTAL
Intervention: Zinc acetate hydrate (ZAH; 50 mg/day)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Polaprezinc (PPZ; 34 mg/day)
Number of subjects: 91
Study: 30500960

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol for skin antisepsis
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Iodine-alcohol for skin antisepsis
Number of subjects: 1038

Group type: EXPERIMENTAL
Intervention: Hysterotomy extension
Number of subjects: 1038
Study: 27638233

Group type: EXPERIMENTAL
Intervention: Change in eGFR in the 1st year
Number of subjects: 6934

Group type: EXPERIMENTAL
Intervention: Change in eGFR over 36 months
Number of subjects: 6934

Group type: EXPERIMENTAL
Intervention: Deterioration in eGFR ≥1 KDOQI class of CKD after 3 years
Number of subjects: 6934

Group type: EXPERIMENTAL
Intervention: Deterioration in eGFR >15 mL•min‐1•1.73 m‐2 in the 1st 12 months
Number of subjects: 6934

Group type: EXPERIMENTAL
Intervention: Lower eGFR associated with outcomes
Number of subjects: 6934

Group type: EXPERIMENTAL
Intervention: Deterioration in eGFR over the 1st year
Number of subjects: 6934

Group type: EXPERIMENTAL
Intervention: Deterioration in eGFR >15 mL•min‐1•1.73 m‐2 in the 1st year
Number of subjects: 6934
Study: 25794285

Group type: EXPERIMENTAL
Intervention: Escitalopram (10.0 ± 4.0 mg/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sertraline (78.6 ± 26.7 mg/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Paroxetine controlled-release formulation (18.8 ± 8.8 mg/day)
Number of subjects: 41
Study: 23453932

Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo rTMS (sham)
Number of subjects: 8
Study: 21856692

Group type: EXPERIMENTAL
Intervention: 10 week physiotherapy led group delivered strength and balance training programme with supplementary home exercises
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study: 19557566

Group type: EXPERIMENTAL
Intervention: Infrared (IR) treatment for 20 minutes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US) treatment for 10 minutes
Number of subjects: 21
Study: 17284134

Group type: EXPERIMENTAL
Intervention: Insight score (measured by Birchwood Insight Scale)
Number of subjects: 0
Study: 16129844

Group type: EXPERIMENTAL
Intervention: G‐CSF schedule 5 (300 microg/d days 8 and 12)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: G‐CSF (any schedule)
Number of subjects: 506
Study: 11166906

Group type: EXPERIMENTAL
Intervention: vCP205 vaccine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: vCP205 and SF-2 rgp120 subunit vaccines
Number of subjects: 72
Study: 9499214

Group type: EXPERIMENTAL
Intervention: IDDM patients
Number of subjects: 99

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 99